Aimia Inc. (LON:0UGP)
London · Delayed Price · Currency is GBP · Price in CAD | Market Cap | 131.30M -13.7% |
| Revenue (ttm) | 219.88M +0.1% |
| Net Income | 13.32M |
| EPS | 0.15 |
| Shares Out | n/a |
| PE Ratio | 9.86 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13 |
| Open | 2.760 |
| Previous Close | 2.880 |
| Day's Range | 2.720 - 2.760 |
| 52-Week Range | 2.560 - 3.360 |
| Beta | 1.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2026 |
About Aimia
Aimia Inc. operates as a diversified conglomerate in Europe, Asia, Oceania, the Americas, Africa, and the Middle East. It operates in three segments: Bozzetto, Cortland International, and Holdings. The company provides specialty chemicals, textiles, and water and dispersion chemical solutions in various applications, including textile, home and personal care, plasterboard, and agrochemical markets; designs, manufactures, and supplies synthetic fiber ropes, as well as offers netting solutions slings, and tethers for the fishing and aquaculture, ... [Read more]
News
Aimia Q2 Earnings Call Highlights
Aimia TSE: AIM reported a second-quarter marked by the sale of Bozzetto, higher net book value per share and steps to reduce debt costs, while management said it expects improving conditions at its Co...
Aimia Earnings Call Transcript: Q2 2026
Bozzetto sale drove a 22% increase in net book value per share and boosted liquidity, while Cortland faced lower revenue but expects improved sales and margins in the second half of 2026. Strategic capital deployment and a U.K. listing remain key priorities.
Aimia Earnings release: Q2 2026
Aimia released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Aimia Registration statement: Q2 2026
Aimia filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Aimia Registration statement: Q2 2026
Aimia filed a registration statement on August 11, 2026, providing details about a securities offering with the SEC.
Aimia Slides: Q2 2026
Aimia has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 11, 2026.
AIM ImmunoTech Releases Q2 2026 Financial Results
AIM ImmunoTech Inc. The post AIM ImmunoTech Releases Q2 2026 Financial Results first appeared on Alphastreet .
AIM Doses Last Patient Early In Phase 2 DURIPANC For Ampligen In Treating Pancreatic Cancer
(RTTNews) - AIM ImmunoTech Inc. (AIM), an immuno-pharma company, on Monday announced the dosing of the final patient in the Phase 2 DURIPANC trial evaluating Ampligen in combination with Imfinzi treat...
SMALL CAP IDEA: Three brokers dominate AIM as the junior market keeps shrinking
For the first time since records began in 2013, three mid-market investment banks share first place in the rankings for clients in the FTSE AIM 100.
SMALL CAP MOVERS: AIM suffers as SpaceX pulls £270 million from Britain
The record SpaceX flotation on the Nasdaq has pulled an estimated £270 million of British retail money across the Atlantic, and London's junior market has felt the drain.
AIM Market Roundup: GCM Resources, PCI-PAL, Empresaria
GCM Resources, PCI-Pal, Empresaria are today's top risers, while AB Dynamics, Mothercare take the biggest fall on AIM
AIM Market Roundup: Mothercare, Getech, Shearwater
Mothercare, Getech, Shearwater are today's top risers, while Forgent, Orcadian Energy take the biggest fall on AIM
Volex completes long-awaited move to London’s Main Market
Volex moves from AIM to LSE Main Market, citing growth to $1.2bn revenue and $2bn target under Nat Rothschild.
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical
AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.
SMALL CAP MOVERS: Scancell heads to Nasdaq as Aim's headcount falls to 612
Scancell Holdings saw its shares drop 27 per cent this week, but the movement obscures the real story, which is a largely positive one for investors.
Takeovers now the leading cause of AIM delistings
Takeovers have become the biggest reason companies leave AIM, underscoring concerns about the long-term decline of the junior stock market.
Aimia Q1 Earnings Call Highlights
Aimia TSE: AIM said its first quarter was marked by progress on the planned sale of specialty chemicals business Bozzetto, continued efforts to reduce holding company costs and a weaker sales performa...
Aimia Earnings Call Transcript: Q1 2026
Q1 2026 saw the Bozzetto divestiture advance, with regulatory approvals secured and closing imminent. Cortland's revenue and EBITDA declined year-over-year due to sector weakness and geopolitical pressures, but leadership changes and market initiatives are expected to drive improvement in H2.
Aimia Earnings release: Q1 2026
Aimia released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Aimia Slides: Q1 2026
Aimia has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.
Aimia Earnings Call Transcript: Q4 2025
Annual guidance met with strong EBITDA and cash growth; Bozzetto divestiture to generate significant liquidity for new investments and debt reduction. Holdco costs reduced, share buybacks ongoing, and acquisition focus shifts to undervalued global opportunities.
Aimia Earnings release: Q4 2025
Aimia released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Aimia Slides: Q4 2025
Aimia has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 24, 2026.
Aimia downgraded to Hold from Buy at TD Securities
TD Securities analyst Brian Morrison downgraded Aimia (AIMFF) to Hold from Buy with a C$3 price target after the company announced an agreement to sell Bozzetto.
Aimia Transcript: M&A announcement
The sale of Bozzetto will generate CAD 265–271 million in proceeds, enabling debt reduction and redeployment into undervalued acquisitions, while unlocking significant tax loss utilization. The transaction is expected to close within three months, with a focus on enhancing shareholder value and long-term capital allocation.